Company news
Ix Biopharma Ltd. (SGX:42C) news
Ix Biopharma Ltd. news releases on 6ix. Latest, Jun 28, 2021: General Announcement::Press Release: iX Biopharma Commences Supply of Medicinal Cannabis Wafers…
Press releases & updates
General Announcement::Press Release: iX Biopharma Commences Supply of Medicinal Cannabis Wafers to Brazil
June 28, 2021
IX Biopharma : is pleased to announce that it will supply its novel Wafermine sublingual ketamine wafers in a pilot study funded by Chris O’Brien Lifehouse, one of Australia’s leading comprehensive cancer hospitals in Camperdown, Sydney. The study will evaluate the efficacy, acceptability, safety and tolerability of Wafermine administered as a first-line treatment for patients with advanced cancer suffering from moderate to severe pain.
June 15, 2021
IX Biopharma : Expands Wafer Production Capacity to Meet Growing Demand
June 2, 2021
IX Biopharma : is pleased to announce that the United States Food and Drug Administration (US FDA) has granted the Company an orphan drug designation for treatment of patients with Complex Regional Pain Syndrome (CRPS) with ketamine.
May 18, 2021
IX Biopharma : is pleased to announce that it has received positive feedback from the European Medicines Agency (EMA) in its scientific advice to the Company regarding its Phase 3 clinical development programme for Wafermine, its sublingual ketamine wafer, for registration in Europe.
November 10, 2020
IX Biopharma : obtains approval and registration of Silcap for the treatment of male erectile dysfunction in Singapore
October 21, 2020
IX Biopharma : obtains approval and registration of Silcap® for the treatment of male erectile dysfunction in Singapore
October 20, 2020